Press release
Epilepsy Clinical Trials 2023, Pipeline Drugs and Companies Insight Report: Analysis of Drugs, MOA, ROA, and Recent Developments by DelveInsight
Epilepsy Clinical Trials
To know more in detail about Epilepsy Pipeline report, click here: https://www.delveinsight.com/report-store/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the essential takeaways from the Epilepsy Pipeline report:
• DelveInsight's Epilepsy Pipeline analysis depicts the space with 70+ active players working to develop 70+ pipeline therapies.
• Major pharmaceutical companies are developing potential drug candidates to improve the Epilepsy treatment scenario, such as Otsuka Pharmaceutical Co. Ltd, Cerebral Therapeutics LLC, Marinus Pharmaceuticals, Xenon Pharmaceuticals, PTC Therapeutics, Eisai, Longboard Pharmaceuticals, Neurocrine Biosciences, and others.
• Key Epilepsy pipeline therapies such as OPC-214870, CT-010, Ganaxolone, XEN496, Vatiquinone E-2730, LP352, NBI 827104, and others are under investigation in different phases of clinical trials.
• In January 2021, Addex Therapeutics announced that its partner Janssen Pharmaceuticals had received FDA's Investigational New Drug (IND) approval to begin a Phase IIa proof of concept study with the selective metabotropic glutamate type 2 (mGlu2) receptor positive allosteric modulator (PAM), JNJ-40411813 (ADX71149), in patients with Epilepsy.
• In October 2020, PTC Therapeutics announced the initiation of a registration-directed Phase II/III clinical trial to evaluate vatiquinone (PTC743) in patients with mitochondrial Epilepsy, the highly morbid condition of refractory seizures in children with inherited mitochondrial disease.
Request for Epilepsy sample report to learn more about trends in specific geographies @ Epilepsy Emerging Therapies and Forecast: https://www.delveinsight.com/report-store/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
The Epilepsy pipeline report lays down detailed profiles of the pipeline assets, inactive and dormant assets, comparative analysis of clinical and non-clinical stage Epilepsy products, comprehensive assessment of driving and restraining factors, and opportunities as well as risks in the Epilepsy pipeline landscape.
Epilepsy Overview
Epilepsy is a chronic neurological disorder characterized by frequent and recurring seizures leading to unusual behaviour. The primary cause of Epilepsy is not clear, but it is noted that any change in the nerve cells, neurons, and the brain resulting in abnormal signals can be the possible reason.
The most common symptom of Epilepsy includes seizures; however, additional symptoms like convulsion without fever, low consciousness, less awareness, loss of taste, smell, sight, hearing, etc., can also be present.
For further information about Epilepsy treatment and pipeline therapies, visit @ Epilepsy Pipeline Assessment: https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Epilepsy Pipeline Drugs
• OPC-214870: Otsuka Pharmaceutical Co. Ltd
• CT-010: Cerebral Therapeutics LLC
• Ganaxolone: Marinus Pharmaceuticals
• XEN496: Xenon Pharmaceuticals
• Vatiquinone: PTC Therapeutics
• E-2730: Eisai
• NBI 827104: Neurocrine Biosciences
Request for Sample to know more @ Epilepsy Pipeline Analysis and Trends: https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Epilepsy Therapeutics Assessment
The Epilepsy Pipeline report proffers an integral view of the Epilepsy emerging novel therapies segregated by Stage, Product Type, Route of Administration, Molecule Type, and Mechanism of Action.
By Product Type
• Mono
• Combination
• Mono/Combination
By Stage
• Discovery
• Pre-clinical
• Phase I
• Phase II
• Phase III
• Pre-registration
By Route of Administration
• Subcutaneous
• Intravenous
• Oral
• Intraventricular
• Inhalation
By Molecule Type
• Gene therapy
• Stem cell therapy
• Small molecules
• Pyridines
By Mechanism of Action
• 4-aminobutyrate transaminase inhibitors
• GABA A receptor agonists
• KCNQ potassium channel agonists
• NQO1 modulators
• Serotonin receptor agonists
• T type calcium channel antagonists
By Targets
• GABA A receptor
• KCNQ potassium channel
• Serotonin receptor
• NQO1
• T type calcium channel
• Synaptic transmission
Scope of the Epilepsy Pipeline Report
• Coverage: Global
• Major Players: Otsuka Pharmaceutical Co. Ltd, Cerebral Therapeutics LLC, Marinus Pharmaceuticals, Xenon Pharmaceuticals, PTC Therapeutics, Eisai, Longboard Pharmaceuticals, Neurocrine Biosciences, and others.
• Key Epilepsy Pipeline Therapies: OPC-214870, CT-010, Ganaxolone, XEN496, Vatiquinone E-2730, LP352, NBI 827104, and others.
Dive deep into rich insights of Epilepsy novel and emerging drugs and their analysis @ Epilepsy Pipeline Emerging Novel Therapies: https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1 Introduction
2 Executive Summary
3 Epilepsy: Overview
4 Epilepsy - Analytical Perspective In-depth Commercial Assessment
5 Pipeline Therapeutics
6 Late Stage Products (Phase III)
7 Late Stage Products (Phase II/III)
8 Mid Stage Products (Phase II)
9 Early Stage Products (Phase I)
10 Therapeutic Assessment
11 Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Epilepsy Key Companies
14 Epilepsy Key Products
15 Epilepsy- Unmet Needs
16 Epilepsy- Market Drivers and Barriers
17 Epilepsy- Future Perspectives and Conclusion
18 Epilepsy Analyst Views
19 Appendix
20 About DelveInsight
Get Epilepsy customized report @ Epilepsy Emerging Therapies: https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Trending Reports:
• Onycholysis Market: https://www.delveinsight.com/report-store/onycholysis-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Acral Lentiginous Melanoma Market: https://www.delveinsight.com/report-store/acral-lentiginous-melanoma-market
• Central Serous Chorioretinopathy Market: https://www.delveinsight.com/report-store/central-serous-chorioretinopathy-market
• Cervical Cancer Market Size: https://www.delveinsight.com/report-store/cervical-cancer-market
• Chronic Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Chronic Lymphocytic Leukemia Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Exocrine Pancreatic Insufficiency Market: https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-epi-market
• Hepatic Encephalopathy Market: https://www.delveinsight.com/report-store/hepatic-encephalopathy-market
• Hyperkalemia Market: https://www.delveinsight.com/report-store/hyperkalemia-treatment-market
• Juvenile Rheumatoid Arthritis Market: https://www.delveinsight.com/report-store/juvenile-rheumatoid-arthritis-market
• Opioid Induced Constipation Market: https://www.delveinsight.com/report-store/opioid-induced-constipation-market
• Osteosarcoma Market: https://www.delveinsight.com/infographics/osteosarcoma-market
• Triple Negative Breast Cancer Market: https://www.delveinsight.com/report-store/triple-negative-breast-cancer-tnbc-market
• Acute Lung Injury Market: https://www.delveinsight.com/report-store/acute-lung-injury-market
• Aortic Stenosis Market: https://www.delveinsight.com/report-store/aortic-stenosis-market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Epilepsy Clinical Trials 2023, Pipeline Drugs and Companies Insight Report: Analysis of Drugs, MOA, ROA, and Recent Developments by DelveInsight here
News-ID: 2869775 • Views: …
More Releases from DelveInsight Business Research
Von Willebrand Disease Market Insights Highlight Expanding Outlook Till 2034, De …
DelveInsight's "Von Willebrand Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Von Willebrand Disease, historical and forecasted epidemiology as well as the Von Willebrand Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Von Willebrand Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Von Willebrand Disease…
Global Artificial Kidney Market to reach USD 6.09 billion by 2032 at a CAGR of 1 …
According to DelveInsight's analysis, The growing demand for artificial kidneys is primarily fueled by the increasing prevalence of kidney failure and end-stage renal disease (ESRD), alongside a rising incidence of contributing factors such as diabetes, hypertension, and an aging global population. These trends are driving the need for advanced and efficient renal care technologies. Moreover, the expanding preference for home-based dialysis solutions, combined with continuous technological innovations and frequent product…
Global Bladder Scanners Market to grow at a CAGR of 6.12% by 2032, Evaluates Del …
According to DelveInsight's analysis, The growing prevalence of urinary disorders such as incontinence, urinary retention, and overactive bladder especially among the aging population continues to drive demand for bladder scanners. The increasing preference for non-invasive and efficient diagnostic tools is further propelling market growth, as bladder scanners provide a safe, quick, and accurate alternative to traditional catheterization. Their expanding use across hospitals, clinics, and home care settings highlights their clinical…
Global Transdermal Drug Delivery Devices Market to reach USD 121,798.76 million …
According to DelveInsight's analysis, The rising incidence of chronic diseases, along with the growing adoption of advanced third-generation transdermal drug delivery systems, is substantially driving the global market's growth.
DelveInsight's "Transdermal Drug Delivery Devices Market Insights, Competitive Landscape and Market Forecast-2032" report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Transdermal Drug Delivery Devices…
More Releases for Epilepsy
Adult mitochondrial epilepsy presentation
Mitochondrial epilepsy is a rare but severe neurological condition caused by genetic mutations that impair mitochondrial function, disrupting cellular energy production in the brain. Patients often present with seizures, developmental delays, and neurodegeneration. It is closely associated with broader mitochondrial diseases such as MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes) and Leigh syndrome.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72869
Due to its rarity and complexity, treatment options…
Portable Epilepsy Monitoring Market in 2025
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Portable Epilepsy Monitoring Market- (By Product Type (Device Type (Chest Sensor, Watch Sensor, Monitors, Cameras, Mattresses and Pillows, and Others) and Service), By End User (Hospitals, Ambulatory Surgery Centres & Clinics, Neurology Centres, and Home Care Settings)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Global…
Top 10 Epilepsy Companies Analysis (2024)
Epilepsy also known as seizure disorder, is a chronic noncommunicable disease that affects brain. Epilepsy affects people of all races, ethnic backgrounds, genders, and ages.
Get More Details with Sample PDF Copy @ https://www.theinsightpartners.com/sample/TIPRE00016405/?utm_source=OpenPR&utm_medium=10129
Major Companies operating in the Epilepsy Market are:
• Idexx Laboratories Inc.
• PBD Biotech Ltd
• Thermo Fisher Scientific Inc.
• Innovative Diagnostics SAS
• Neogen Corp
• Enfer Labs
• bioMerieux SA
• Ring Biotechnology Co Ltd
• Bionote Inc.
• Shenzhen Bioeasy Biotechnology Co Ltd.
Contact Us:
If you have any queries about this report or if…
Epilepsy Market: Trends, Opportunities, and Challenges
Epilepsy is a neurological disorder characterized by recurrent seizures, which are caused by abnormal electrical activity in the brain. This condition affects millions of people globally, making it one of the most common neurological disorders. As the global burden of epilepsy increases, the demand for effective treatments and solutions continues to grow. The epilepsy market is evolving rapidly, with advancements in medication, diagnostics, and therapeutic technologies. This guest post aims…
Epilepsy Device Market: for Epilepsy Devices Poised to Exceed $1 Billion by 2031 …
The global epilepsy devices market isx experiencing a remarkable surge, poised to exceed a valuation of $1.1 billion by 2031, as revealed by the latest market analysis. According to the report released by Allied Market Research, the market was valued at $675.23 million in 2021 and is projected to grow at a CAGR of 5.1% from 2022 to 2031.
𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐅𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲: https://www.alliedmarketresearch.com/request-sample/A14821
Epilepsy devices play…
Epilepsy with Myoclonic - Atonic Seizures Therapeutics Market - Breaking the Sei …
Newark, New Castle, USA: The "Epilepsy with Myoclonic-Atonic Seizures Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Epilepsy with Myoclonic - Atonic Seizures Therapeutics Market: https://www.growthplusreports.com/report/epilepsy-with-myoclonic-atonic-seizures-therapeutics-market/8029
This…
